Beta Drugs LimitedQ1 FY27 Results & Financial Update
Beta Drugs Limited: Q1 FY27 consolidated results and company financials – revenue ₹125.55 Cr, PAT ₹16.49 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Beta Drugs price & chart
Market price₹1,971.00
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Beta Drugs Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the quarter ended June 30, 2026 (Q1 FY27), Beta Drugs Limited reported consolidated revenue from operations of INR 125.55 crore (INR 1,255.50 million), alongside total revenue of INR 127.13 crore.
Profit before tax (PBT) for the quarter stood at INR 22.04 crore, while profit after tax (PAT) reached INR 16.49 crore, yielding a net profit margin of approximately 13.13%.
Diluted earnings per share (EPS) for the quarter was reported at INR 14.78, reflecting robust earnings growth compared to preceding periods.
According to accompanying investor presentation disclosures, consolidated revenue grew by 25.2% year-on-year from INR 100.20 crore in Q1 FY26, driven by strong operational momentum across business verticals.
The quarter's performance benefited from the inclusion of Nivian Lifesciences as an IVF subsidiary starting April 2026, alongside stellar performance in the branded oncology and contract manufacturing segments.
Gross margins improved significantly to 56.6% compared to 50.4% in Q1 FY26, aided by a favorable product mix shifting toward higher-margin branded and export offerings.
EBITDA for the quarter rose by 39.1% year-on-year to INR 27.40 crore (INR 274 million), with EBITDA margins expanding by 217 basis points year-on-year to 21.83%.
01 · Business model
What does Beta Drugs do?
Beta Drugs Limited is a specialized Indian pharmaceutical company focused primarily on oncology, offering a comprehensive portfolio spanning chemotherapy, targeted therapies, and supportive care solutions under the Adley brand.
The company operates a diversified business model comprising domestic branded formulations, contract manufacturing (CMO) services for marquee pharmaceutical clients, and active pharmaceutical ingredients (APIs) that provide a strong backward-integration advantage.
Manufacturing operations are conducted across three WHO-GMP certified facilities located in Baddi and Barotiwala in Himachal Pradesh, and Derabassi in Punjab, with certain facilities holding international accreditations such as ANVISA, INVIMA, and COFEPRIS.
Beta Drugs has expanded its addressable market beyond oncology through strategic forays into dermatology and assisted reproductive care (IVF), the latter bolstered by the acquisition of a 66.09% stake in Nivian Lifesciences Pvt. Ltd. in April 2026.
02 · Historical context
What shaped the business before this quarter
Beta Drugs Ltd. was established in 2005 by the late Shri. Vijay Kumar Batra as part of the Adley Group.
Set up the first dedicated oncology manufacturing unit under Adley Formulations Pvt Ltd in 2008.
Established a new state-of-the-art oncology formulation facility in Nandpur (2014) and commenced in-house API production via Adley Labs (2017), followed by listing on the NSE SME platform.
Secured INR 117 crore via Compulsorily Convertible Debentures (CCDs) from global institutional investors HealthQuad and Tanas Capital to fund future growth.
Migrated from the NSE SME platform to the NSE Mainboard in 2025, having been recognized by Forbes Asia 'Under a Billion' for three consecutive years (2023, 2024, and 2025).
Entered the high-growth IVF segment in April 2026 by acquiring a 66.09% stake in Nivian Lifesciences Pvt. Ltd.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹125.55 Cr |
| Total income | ₹127.13 Cr |
| Profit before tax | ₹22.04 Cr |
| Profit after tax | ₹16.49 Cr |
| EPS | ₹14.78 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Delivered robust year-on-year growth of 47% in the branded oncology segment, generating INR 33.0 crore (INR 330 million) on strong traction in existing products and new product acceptance.
CMO business grew by 41% year-on-year to INR 47.4 crore (INR 474 million), supported by repeat business from key marquee clients and proprietary Novel Drug Delivery System (NDDS) product offerings.
Export operations contributed INR 17.2 crore (INR 172 million) in revenue during the quarter, with management anticipating accelerated order inflows across international markets.
The newly acquired subsidiary Nivian Lifesciences contributed INR 15.1 crore (INR 151 million) in Q1 FY27, delivering 45% YoY growth driven by deeper market penetration and full-quarter contribution from Q4 FY26 product launches.
What drove margins
Gross margins improved to 56.6% in Q1 FY27 from 50.4% in Q1 FY26, driven by a favorable shift toward higher-margin branded formulations and export business.
EBITDA margin expanded by 217 basis points year-on-year to 21.83% (up from 19.66% in Q1 FY26), reflecting improved operating efficiencies and scale economics across manufacturing plants.
In-house API manufacturing utilized for over 80% of company formulations helps maintain strict cost control and protects margins against external raw material volatility.
Finance costs declined year-on-year to INR 2.56 crore in Q1 FY27 from INR 3.32 crore in Q1 FY26, easing pressure on bottom-line profitability.
05 · Demand, customers & order book
Where demand is coming from
CMO division serves over 104 clients including major pharmaceutical entities such as Glenmark, Alkem, Intas, Torrent Pharma, and Cadila Pharmaceuticals.
The Nivian IVF division reaches over 1,500 fertility clinics, 1,500 IVF labs, and 1,209 gynaecologists across 15 states and union territories in India.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Total branded revenue reached INR 48.1 crore in Q1 FY27 (including INR 15.1 crore from the newly consolidated Nivian IVF subsidiary; base branded oncology contributed INR 33.0 crore).
Generated INR 47.4 crore, serving over 104 clients with a 95% repeat business rate from key institutional customers.
API segment generated INR 8.3 crore in external and captive revenue, supporting internal formulation requirements and margin defense.
Dermatology portfolio contributed INR 4.5 crore, supported by exclusive partnerships with European and Greek brands for advanced aesthetic and anti-aging solutions.
Geography and market mix
Products are exported to over 25 countries, backed by 280+ product registrations and a robust regulatory filing pipeline across LATAM, APAC, MENA, Africa, and CIS regions.
Export distribution is led by LATAM (42%) and APAC (32%), followed by Africa (19%) and MENA (7%).
Branded formulations maintain availability across more than 85% of corporate and government hospitals in India.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Facility utilization stood at 67.30% for the Nandpur plant, 79.42% for the Derabassi API plant, and 69.93% for the Barotiwala formulation plant.
Projects, capex and execution
Continued investments in EU-GMP aligned infrastructure expansions, advanced microbiology laboratories, and automated HVAC systems across manufacturing units to support global regulatory compliance.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Successfully integrated Nivian Lifesciences in April 2026 (holding a 66.09% stake) to establish a firm foothold in assisted reproductive technology and fertility treatments.
Continued investment in Novel Drug Delivery Systems (NDDS), including liposomes, nanoparticles, and microparticle technologies, supporting a robust pipeline of first-to-launch specialty products.
09 · Reported developments
What changed operationally
Consolidated PAT surged by 41.0% year-on-year to INR 16.49 crore in Q1 FY27, supported by strong revenue expansion and operating leverage.
Seamless operational consolidation of Nivian Lifesciences contributed immediate top-line revenue and expanded the company's addressable specialty healthcare market.
10 · Pressure points & risks
What is not going smoothly
Other income declined year-on-year to INR 1.58 crore in Q1 FY27 from INR 2.99 crore in Q1 FY26, partially tempering total revenue growth relative to operational revenue.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Historical working capital days stood at 107 days in FY26, reflecting the capital-intensive nature of scaling pharmaceutical manufacturing and distribution inventory.
Capital allocation & funding
Maintained a conservative debt-to-equity ratio of 0.60x as of FY26 following institutional investments received via CCDs from HealthQuad and Tanas Capital.
12 · Management guidance & targets
What management is targeting from here
Management reaffirmed its Vision 2030 targets, guiding for consolidated revenue growth of 20% to 25% for FY27.
Aims to derive over 50% of total revenue from own branded products over the long term.
13 · Beyond the numbers
What changed beyond the numbers
Reported update
Forbes Recognition
Awarded in Forbes Asia 'Under a Billion' for three consecutive years (2023, 2024, and 2025).
14 · Previous-quarter changes
What changed since the previous quarter
Consolidated revenue from operations increased sequentially from INR 93.95 crore in Q4 FY26 to INR 125.55 crore in Q1 FY27.
PAT increased sequentially from INR 9.05 crore in Q4 FY26 to INR 16.49 crore in Q1 FY27, driven by higher seasonal demand and operating leverage.
15 · Key Q&A
The quarter, answered directly
What does Beta Drugs do?
Beta Drugs Limited is a specialized Indian pharmaceutical company focused primarily on oncology, offering a comprehensive portfolio spanning chemotherapy, targeted therapies, and supportive care solutions under the Adley brand.
What is the clearest takeaway from Q1 FY27?
For the quarter ended June 30, 2026 (Q1 FY27), Beta Drugs Limited reported consolidated revenue from operations of INR 125.55 crore (INR 1,255.50 million), alongside total revenue of INR 127.13 crore.
What drove revenue or demand?
Delivered robust year-on-year growth of 47% in the branded oncology segment, generating INR 33.0 crore (INR 330 million) on strong traction in existing products and new product acceptance.
What mattered most for margins or profitability?
Gross margins improved to 56.6% in Q1 FY27 from 50.4% in Q1 FY26, driven by a favorable shift toward higher-margin branded formulations and export business.
What changed operationally beyond the headline numbers?
Facility utilization stood at 67.30% for the Nandpur plant, 79.42% for the Derabassi API plant, and 69.93% for the Barotiwala formulation plant.
What is management guiding or targeting from here?
Management reaffirmed its Vision 2030 targets, guiding for consolidated revenue growth of 20% to 25% for FY27.
16 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
17 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Export Momentum Tracking: Monitor the acceleration of international order inflows and regulatory dossier approvals across LATAM, CIS, and African markets.
- 02
IVF Integration Synergy: Track revenue contribution and margin evolution from the newly integrated Nivian Lifesciences IVF subsidiary over subsequent quarters of FY27.
- 03
New Product Launches: Observe commercial progress on the robust pipeline of NDDS and first-to-launch specialty oncology formulations.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.